- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A phenocopy signature of TP53 loss predicts response to chemotherapy ; volume:8 ; number:1 ; day:2 ; month:10 ; year:2024 ; pages:1-10 ; date:12.2024
npj precision oncology ; 8, Heft 1 (2.10.2024), 1-10, 12.2024
- Urheber
-
Bakhtiar, Hamza
Sharifi, Marina N.
Helzer, Kyle T.
Shi, Yue
Bootsma, Matthew L.
Shang, Tianfu A.
Chrostek, Matthew R.
Berg, Tracy J.
Carson Callahan, S.
Carreno, Viridiana
Blitzer, Grace C.
West, Malinda T.
O’Regan, Ruth M.
Wisinski, Kari B.
Sjöström, Martin
Zhao, Shuang G.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-024-00722-7
- URN
-
urn:nbn:de:101:1-2412192106215.487303043397
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bakhtiar, Hamza
- Sharifi, Marina N.
- Helzer, Kyle T.
- Shi, Yue
- Bootsma, Matthew L.
- Shang, Tianfu A.
- Chrostek, Matthew R.
- Berg, Tracy J.
- Carson Callahan, S.
- Carreno, Viridiana
- Blitzer, Grace C.
- West, Malinda T.
- O’Regan, Ruth M.
- Wisinski, Kari B.
- Sjöström, Martin
- Zhao, Shuang G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
Convergent TP53 loss and evolvability in cancer
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients
A pseudogene-signature in glioma predicts survival
Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
A novel methylation signature predicts radiotherapy sensitivity in glioma
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection
Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
Convergent TP53 loss and evolvability in cancer
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients
A pseudogene-signature in glioma predicts survival
Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
A novel methylation signature predicts radiotherapy sensitivity in glioma
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection
Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
Convergent TP53 loss and evolvability in cancer
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients
A pseudogene-signature in glioma predicts survival
Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
A novel methylation signature predicts radiotherapy sensitivity in glioma
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection